Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies LONDON , Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

MedTech Insights report series analyzes the impact of recent breakthroughs in pulsed-field ablation, signaling its promising future in the electrophysiology mapping and ablation device market LONDON , Dec. 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of a new special report series,  Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific.

Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm

Clarivate has turned organic growth positive and has visible tailwinds that could drive organic growth higher. The company reported positive organic growth in 3Q23, beating consensus estimates for revenue and EBITDA margins. The A&G and LSH segments showed strong organic growth, and the IP segment is expected to recover as macro headwinds ease.

Clarivate: Rating Upgrade As Organic Growth Turns Positive

Informatica

Investors interested in stocks from the Internet - Software sector have probably already heard of Clarivate PLC (CLVT) and Informatica Inc. (INFA). But which of these two stocks is more attractive to value investors?

CLVT vs. INFA: Which Stock Is the Better Value Option?

New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON , Dec. 5, 2023 /PRNewswire/ --  Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence by Clarivate. The integrated workflow provides customers with a diverse array of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose and more.

Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development

Concentration of top talent with 10 countries/regions representing over 80% of list LONDON , Nov. 15, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today revealed its 2023 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,849 Highly Cited Researchers in 2023, from more than 1,300 institutions in 67 nations and regions.

Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List

LONDON , Nov. 8, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today that Jonathan Gear, Chief Executive Officer, will present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on Tuesday, November 14, 2023 at 1:20 pm Eastern Time. The live webcast can be accessed at https://www.veracast.com/webcasts/rbc/tmit2023/67C540.cfm and will be available for replay.

Clarivate to Present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023

Clarivate Plc (NYSE:CLVT ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Mark Donohue - Vice President, Investor Relations Jonathan Gear - Chief Executive Officer Jonathan Collins - Executive Vice President and Chief Financial Officer Conference Call Participants Toni Kaplan - Morgan Stanley Manav Patnaik - Barclays Surinder Thind - Jefferies Andrew Nicholas - William Blair John Mazzoni - Wells Fargo Owen Lau - Oppenheimer Ashish Sabadra - RBC Capital Markets Peter Christiansen - Citi George Tong - Goldman Sachs Operator Good morning. Thank you for attending today's Clarivate Third Quarter 2023 Earnings Call.

Clarivate Plc (CLVT) Q3 2023 Earnings Call Transcript

The headline numbers for Clarivate PLC (CLVT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Clarivate PLC (CLVT) Q3 Earnings: A Look at Key Metrics

Clarivate PLC (CLVT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.20 per share a year ago.

Clarivate PLC (CLVT) Beats Q3 Earnings and Revenue Estimates

— Reaffirms 2023 Outlook — LONDON , Nov. 7, 2023 /PRNewswire/ -- Clarivate Plc - (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today reported results for the third quarter. Third  Quarter 2023 Financial Highlights Revenues of $647.2 million increased 1.8%, and decreased 1.3% at constant currency(2) Organic revenues increased 1.7% driven by an increase in transactional and other revenues of 3.5%, subscription revenues of 1.3% and re-occurring revenues of 0.5% Net loss attributable to ordinary shares of $6.6 million; Net loss per diluted share of $0.01 Adjusted Net Income(1) of $152.6 million increased 6.2%; Adjusted Income per diluted share(1) of $0.21 increased 5.0% or $0.01 Adjusted EBITDA(1) of $281.4 million increased 3.6% driven by cost savings from integration programs; Adjusted EBITDA Margin(1) of 43.5% increased 80 basis points Net cash provided by operating activities decreased $44.4 million to $163.4 million; Free cash flow(1) decreased $38.7 million to $101.7 million, driven by timing-related, in quarter working capital requirements Nine Months Ended September 30, 2023 Financial Highlights Revenues of $1,945.1 million decreased 2.0%, and 2.6% at constant currency(2), driven primarily by the divestiture of MarkMonitor in October 2022, for which there were no comparable amounts in the current year period Organic revenues increased 0.3% as an increase in subscription revenues of 2.3% was offset by a decline in re-occurring revenues of 1.0% and transactional and other revenues of 4.3% Net loss attributable to ordinary shares of $123.6 million; Net loss per diluted share of $0.18 Adjusted Net Income(1) of $435.7 million decreased 6.1%; Adjusted Income per diluted share(1) of $0.59 decreased 6.3% or $0.04 Adjusted EBITDA(1) of $819.0 million increased 1.3% driven by cost savings from integration programs; Adjusted EBITDA Margin(1) of 42.1% increased 140 basis points Net cash provided by operating activities increased $180.9 million to $553.3 million; Free cash flow(1) increased $158.8 million to $374.7 million "Our improved third quarter performance was driven by organic growth from our Academia & Government and Life Sciences & Healthcare (LS&H) segments, each delivering their highest quarterly revenue growth rate over the past year," said Jonathan Gear, Chief Executive Officer.

Clarivate Reports Third Quarter 2023 Results

Clarivate PLC (CLVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: Should You Buy?

Institute for Scientific Information shows China matching research productivity with excellence, diversifying its research economy and expanding its collaboration network LONDON , Oct. 31, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released a report from the Institute for Scientific Information (ISI)™ which reveals that China's* research economy has seen a dramatic increase in quality and its research is increasingly valued beyond its borders. China is also diversifying beyond its traditional strengths in technology and physical sciences to focus on new areas such as biomolecular science.

Clarivate Report Reveals China Challenging U.S. Research Dominance, Signaling Future Research Ambitions

Leveraging the strengths of the two organizations to aid libraries through dedicated resources and advocacy LONDON , Oct. 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced a partnership with EveryLibrary, the non-partisan advocacy organization for libraries. As part of the partnership, Clarivate™ has made a commitment to advance EveryLibrary's mission to safeguard and support libraries in the U.S. Bar Veinstein, President, Academia & Government, Clarivate said: "Libraries transform the world through their critical role in promoting literacy, education, equal access to information and community engagement.

Clarivate Partners with EveryLibrary to Support and Nurture Libraries in the U.S.

Three-part, in-depth analysis of biopharma investments in obesity medications highlights potential impact on patient population historically faced with limited options LONDON , Oct. 24, 2023 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, examines the impact of emerging obesity medicines in a new three-part series, The Rise of Obesity. The special coverage offers in-depth analysis of how the anticipated multibillion-dollar market potential for obesity medications in the coming years will impact biopharma, insurance companies and a patient population in need of safer options.

BioWorld by Clarivate Examines Impact of Emerging Medicines on Obesity

Clarivate PLC (CLVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Clarivate PLC (CLVT) Beat Estimates Again in Its Next Earnings Report?

Strengthening U.S. government libraries with comprehensive solutions across Clarivate LONDON , Oct. 18, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the renewal of its contract with the Federal Library and Information Network (FEDLINK). This contract is in addition to the contract agreed with ProQuest, part of Clarivate™.

Clarivate Renews Partnership with The Federal Library and Information Network

LONDON , Oct. 16, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today it will report its financial results for the third quarter 2023 before the market opens on Tuesday, November 7. The press release and earnings supplement, with accompanying financial information, will be posted on the Clarivate investor website.

Clarivate to Report Third Quarter 2023 Results on November 7, 2023

Different roles within the IP practice and geographies significantly diverge in their attitudes towards AI LONDON , Oct. 12, 2023 /PRNewswire/ --  Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its new report, Redefining AI: How IP practice meets the coming wave. The report explores the effects the rapid advancements in artificial intelligence (AI) will have on IP law, practice and processes, and the legal sector.

Clarivate Report Finds Significant Adoption of AI in IP

Winners include Valley Medical Group, Fairfield Medical Center, Valley Hospital and Ballad Health LONDON , Oct. 11, 2023 /PRNewswire/ -- Today Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced the 2022 winners of the Clarivate Healthcare Business Insights™  annual Revenue Cycle Awards. In its 11th year, the Revenue Cycle Awards recognizes U.S. based healthcare organizations for achieving outstanding performance on revenue cycle KPIs, based on data from their most recent and preceding full fiscal years.

Clarivate Healthcare Business Insights Announces 2022 Revenue Cycle Awards Recipients

75 Citation Laureates named by the Institute for Scientific Information have received a Nobel Prize since 2002 LONDON , Oct. 10, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today celebrates the four new Nobel Laureates who were accurately identified as potential Nobel Prize recipients. Ferenc Krausz, Moungi G.

Clarivate Accurately Forecasts Four New 2023 Nobel Prize Laureates

Improving efficiencies and achieving more unified workflows with cloud-based Ex Libris Alma and Ex Libris Primo, both part of Clarivate LONDON , Oct. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announces that Yale University has selected Clarivate ™ to provide its library services and discovery platforms.  Ex Libris Alma and Ex Libris Primo VE, both part of Clarivate, will provide Yale with a solution that integrates AI (artificial intelligence) and Linked Data to simplify the process for students, researchers and faculty.

Yale University Selects Clarivate to Provide Their Next Library Services and Discovery Platforms

Rapid acceleration in IP creation and scientific knowledge drives growing acceptance of AI and ML in drug discovery and development United States and Mainland China continue to lead innovation and remain at the forefront of AI technology advancement for drug discovery LONDON , Sept. 27, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released its annual Companies to Watch report.

Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report

By incubating new technology with AI capabilities such as Alethea, Clarivate will further accelerate its strategy to advance knowledge through research and education LONDON , Sept. 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced it has established an Academia & Government Innovation Incubator.

Clarivate Establishes Academia & Government Innovation Incubator and Acquires Alethea, an AI Student Engagement Solution

New tool tracks and predicts IP costs more accurately and efficiently LONDON , Sept. 20, 2023 /PRNewswire/ -- Clarivate Plc  (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched Forecast, the next generation artificial intelligence (AI)-driven solution designed to enable intellectual property (IP) professionals worldwide to confidently and efficiently optimize their IP portfolios and strategy.

News for Clarivate Plc Stock (CLVT)